RxDoctor Payments Data

Eshan Patvardhan, MD

Cardiovascular Disease · Dartmouth, MANPI 1497076046

Payments from drug & device makers

$667in general payments, 2019–2025

Across 32 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$249
  • Novartis$147
  • E.r. Squibb & Sons, L.L.C.$128
  • Boston Scientific$23
  • Abbott$22
  • Lexicon Pharmaceuticals, Inc.$22
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$64597%
  • Education$223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$667 in reported general payments places this provider in the 35th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$302,445
Medicare patients
1,087
Services billed
3,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban561$694,704
XareltoRivaroxaban107$122,513
EntrestoSacubitril/Valsartan21$31,476
Repatha SureclickEvolocumab39$28,174
JardianceEmpagliflozin23$27,914
Metoprolol Succinate676$12,767
FarxigaDapagliflozin Propanediol13$8,756
Atorvastatin Calcium515$6,962
Ezetimibe122$5,287
Isosorbide Mononitrate ErIsosorbide Mononitrate229$3,719
Dabigatran EtexilateDabigatran Etexilate Mesylate16$3,552
Amiodarone Hcl76$3,239
Pravastatin Sodium125$2,791
Ranolazine ErRanolazine24$2,300
Bumetanide24$2,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$249$694,704561 claims
Johnson & JohnsonXarelto$17$122,513107 claims
NovartisEntresto$147$31,47621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →